Abstract
In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1β), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease.
Keywords: APA microcapsules, in vivo study, molecular markers, Crohn’s disease, thalidomide.
Current Drug Delivery
Title:Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice
Volume: 11 Issue: 1
Author(s): Marc Fakhoury, Michael Coussa-Charley, Hani Al-Salami, Imen Kahouli and Satya Prakash
Affiliation:
Keywords: APA microcapsules, in vivo study, molecular markers, Crohn’s disease, thalidomide.
Abstract: In this study, we examined the in-vivo characteristics of a novel microencapsulated thalidomide formulation in a murine model of experimental Crohn's disease. Crohn's disease was induced with a single intra-colonic injection of 120 mg/kg of bodyweight of 2,5,6-trinitrobenzene sulfonic acid (TNBS) dissolved in 30% ethanol in Balb/c mice. Level of tumor necrosis factor alpha (TNF-α), interleukin one beta (IL-1β), interleukin 6 (IL-6) and nitric oxide (NO) were measured in tissue homogenate. Moreover, myeloperoxidase (MPO) activity was determined to assess the extent of neutrophil infiltration. Dose response study showed that treating the mice with microencapsulated thalidomide (100 mg/kg of bodyweight) for two weeks significantly decreased the degree of intestinal inflammation related to Crohn’s disease. Higher and lower doses (0, 25, 50 and 200 mg/kg of bodyweight) did not exhibit comparable effects. The present study validates the success of alginate-poly-L-lysine-alginate (APA) microcapsules containing thalidomide in reducing colonic inflammation, and proposes a potential remedy for Crohn’s disease.
Export Options
About this article
Cite this article as:
Fakhoury Marc, Coussa-Charley Michael, Al-Salami Hani, Kahouli Imen and Prakash Satya, Use of Artificial Cell Microcapsule Containing Thalidomide for Treating TNBS-induced Crohn's Disease in Mice, Current Drug Delivery 2014; 11 (1) . https://dx.doi.org/10.2174/156720181101140212170025
DOI https://dx.doi.org/10.2174/156720181101140212170025 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of Glycogen Synthase Kinase 3 in Alzheimer’s Disease
Current Alzheimer Research Zn(L-proline)2: An Efficient and Recyclable Catalytic System for the Asymmetric Multicomponent Synthesis of 2-amino-4H-chromenes in Water Under Controlled Microwave Heating
Current Microwave Chemistry Green Synthesis of Novel Class of Benzazocine Derivatives, their Crystal Structures and Anticancer Activity
Current Organic Synthesis Wrap-and-Strip Technology of Protein–Polyelectrolyte Complex for Biomedical Application
Current Medicinal Chemistry A Review of Ground Glass Opacity Detection Methods in Lung CT Images
Current Medical Imaging The Past, Current Studies and Future of Organometallic <sup>99m</sup>Tc(CO)3 Labeled Peptides and Proteins
Current Pharmaceutical Design Synergistic Effect of Graphene Oxide Coated Nanotised Apigenin with Paclitaxel (GO-NA/PTX): A ROS Dependent Mitochondrial Mediated Apoptosis in Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry Advanced Micro-Nano-Bio Systems for Future Targeted Therapies
Current Nanoscience Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Current Drug Safety Bilitranslocase is Involved in the Uptake of Bromosulfophthalein in Rat and Human Liver
Drug Metabolism Letters In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy Synthesis and Cytotoxic Properties of Halogen and Aryl-/Heteroarylpiperazinyl Derivatives of Benzofurans
Anti-Cancer Agents in Medicinal Chemistry Fatty Acid (FA) Compositions and Trans Content of Frequently Consumed Edible Oils and Fats from Iran’ Market
Current Nutrition & Food Science Meta Analysis of Advanced Cancer Survival Data Using Lognormal Parametric Fitting: A Statistical Method to Identify Effective Treatment Protocols
Current Pharmaceutical Design In Vitro and In Vivo Transformations of Lutein
Mini-Reviews in Organic Chemistry Erythropoiesis Stimulating Agents and Techniques: A Challenge for Doping Analysts
Current Medicinal Chemistry Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients
Current Drug Metabolism β-Galactosylated Alkyl-oligoamine Derivatives of Polyethylenimine Enhanced pDNA Delivery into Hepatic Cells with Reduced Toxicity
Current Nanoscience Protease Analysis by Zymography: A Review on Techniques and Patents
Recent Patents on Biotechnology